Interested in Cartistem Study? On this page, we have collected links for you, where you will receive the most necessary information about Cartistem Study.
https://clinicaltrials.gov/ct2/show/NCT04310215
Mar 17, 2020 · Brief Summary: The purpose of this study is to evaluate the efficacy and safety of adding CARTISTEM® (allogenic umbilical cord blood-derived stem cell product) on microfracture, a currently standard treatment for OLT, in patients with talar chondral or osteochondral defect.
https://clinicaltrials.gov/ct2/show/NCT01733186
Nov 26, 2012 · CARTISTEM®, a combination of human umbilical cord blood-derived mesenchymal stem cells and sodium hyaluronate, is intended to be used as a single-dose cellular therapeutic agent for cartilage regeneration in human subjects with cartilage defects of the knee as a result of ageing, trauma, or degenerative diseases.
http://www.medi-post.com/cartistem/
CARTISTEM® – allogeneic umbilical cord blood-derived mesenchymal stem cells, is used for the treatment of knee cartilage defects in patients with Osteoarthritis (with ICRS grade* IV cartilage defect) caused by degeneration or repetitive trauma. *ICRS grade : A diagnostic criteria used for grading the severity of cartilage defect.
http://www.medi-post.com/stem-cell-therapeutic/2020/07/36655/
The clinical trial of NEUROSTEM ®, which uses mesenchymal stem cells from umbilical cord blood for the treatment of patients with Alzheimer’s disease, started in 2013 and was completed in January 2021 with clinical study report submitted to the Ministry of Food and Drug Safety (MFDS).
We hope you have found all the information you need about Cartistem Study through the links above.
